Contact
Please use this form to send email to PR contact of this press release:
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria
TO: